APRN: Pharmacogenomics and Management of Cardiovascular Disease
Prior to the completion of the Human Genome Project (HGP) in 2003, individual responses to medications were usually termed idiosyncrasies. In addition, ethnic differences were not usually seen as genetic variants, as is the case today. With the identification of single-nucleotide polymorphisms (SNPs, pronounced "snips"), pharmacogenomics and pharmacogenetics (the study of individual genetic variants) have emerged as the newest science to determine genetic variants of populations. There are possibly over 15 million SNPs in the human genome that may or may not cause an obvious variant depending on the location on the gene; therefore, the possibility of drug reactions will become individualized. Application of this knowledge is necessary for proper management of numerous cardiovascular disease processes. The advanced practice nurse needs to incorporate pharmacogenomics and pharmacogenetics into everyday practice to offer optimal treatment for patients.
Purpose/Goal: To provide the advanced practice nurses with an overview of pharmacogenomics and the role it plays in the management of cardiovascular disease.
1. Discuss genomics and its evolving role in pharmacologic therapy.
2. Correlate specific genomic variations with differences in cardiovascular drug metabolism.
Linda A. Howe, CNS, CNE, PhD
The planners and author(s) of this continuing nursing education activity have disclosed no relevant financial relationships with any commercial companies pertaining to this activity.
Contact Hours: 2.4
Expiration Date: 12/31/2014
Pharmacology Hours: 1
Member Price: $40.00
Non-Member Price: $60.00